Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. received an updated ownership report from Invus-affiliated investors and Raymond Debbane. As of December 31, 2025, Invus Public Equities directly held 7,068,444 common shares and Avicenna Life Sci Master Fund held 1,096,930 shares of Tango Therapeutics.
Through a chain of general partners and managing members, including Invus Public Equities Advisors, Invus Global Management, Siren, Avicenna GP and Ulys, Raymond Debbane may be deemed to beneficially own 8,165,374 shares, representing 6.1% of Tango’s common stock, based on 134,593,998 shares outstanding as of October 28, 2025. The reporting group certifies the shares were not acquired to change or influence control of the company.
Adage Capital Management, L.P. and affiliates report a 7.88% beneficial stake in Tango Therapeutics, Inc. They collectively hold 10,607,924 shares of Tango common stock, with shared voting and investment power and no sole authority reported.
The ownership percentage is based on 134,677,094 Tango shares outstanding as of November 1, 2025, as disclosed in a company registration statement. The investors state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. filed an Amendment No. 4 to Schedule 13D/A reporting updated ownership by Third Rock Ventures entities. As of February 6, 2026, Third Rock Ventures IV, L.P. and its affiliated general partners reported shared voting and dispositive power over 6,374,574 shares of Tango common stock, representing approximately 4.74% of outstanding shares, based on 134,593,998 shares outstanding as of October 28, 2025. The amendment states that transactions described in Item 5(c) caused a decrease of over one percentage point in the aggregate ownership previously reported. These changes follow several open-market sales of Tango shares in January and February 2026.
Tango Therapeutics, Inc. received an amended Schedule 13G showing updated ownership by funds managed by Farallon Capital. As of the reporting date, the Farallon Funds hold 13,391,411 common shares and 2,159,792 pre-funded warrants, each warrant exercisable into one share.
The warrants are subject to a 9.99% Beneficial Ownership Limitation, so only 69,804 warrants are currently counted as exercisable within 60 days when calculating beneficial ownership. The amendment also records governance changes at Farallon: Avner A. Husen became a member/manager of the related general partners effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles as of December 31, 2025, and may no longer be deemed beneficial owners. The filing is made on a passive basis under Rule 13d-1(c), with the group certifying the holdings are not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics Chief Financial Officer Daniella Beckman reported new equity awards and related tax sales. On February 2, 2026, she acquired 44,330 shares of common stock for $0, representing restricted stock units that vest in three tranches through February 2029, and received a stock option for 265,980 shares at an exercise price of $11.94 per share, vesting over four years.
On February 3, 2026, she sold 10,204 and 113 shares of common stock at weighted average prices of $12.2573 and $12.8971, respectively, under the company’s automatic “sell-to-cover” policy for tax withholding tied to RSU vesting. After these transactions, she held 184,297 shares of common stock and 265,980 stock options, all reported as directly owned.
Barbara Weber, Director and Executive Chair of Tango Therapeutics, Inc., reported multiple equity transactions. She acquired 37,522 shares of common stock on February 2, 2026 through restricted stock units that vest in full on February 1, 2027, subject to continued service.
On the same date she was granted a stock option for 222,132 shares at an exercise price of $11.94 per share, vesting in 12 equal monthly installments following January 1, 2026. To satisfy tax withholding under the issuer’s sell-to-cover policy, she automatically sold 30,186 shares at a weighted average price of $12.2573 and 333 shares at $12.8971 on February 3, 2026. After these transactions, she directly owned 1,629,254 shares of common stock and 222,132 options.
Tango Therapeutics President of R&D Crystal Adam reported new equity awards and related tax sales of common stock. On February 2, 2026, she received 47,460 restricted stock units, each equal to one share, vesting 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service. She also received a stock option for 284,760 shares at an exercise price of $11.94, vesting 25% on January 1, 2027 and monthly thereafter for three years. To cover tax withholding from RSU vesting under the company’s sell-to-cover policy, she automatically sold 18,251 shares at a weighted average $12.2573 and 201 shares at a weighted average $12.8971 on February 3, 2026. After these transactions, she directly owned 187,218 common shares and 284,760 options.
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025. Vanguard reports no sole voting or dispositive power, with shared voting power over 742,606 shares and shared dispositive power over all 6,750,977 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Tango Therapeutics. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
BlackRock, Inc. reported beneficial ownership of 8,477,165 shares of Tango Therapeutics, Inc. common stock, representing 6.3% of the outstanding class as of 12/31/2025. BlackRock has sole voting power over 8,351,821 of these shares and sole dispositive power over all 8,477,165 shares, with no shared voting or dispositive authority.
The shares are held across certain BlackRock business units, and various underlying clients or beneficiaries have rights to dividends or sale proceeds, but no single other person has more than five percent of Tango's outstanding common shares. BlackRock classifies itself as a parent holding company or control person and states that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Tango Therapeutics.
Tango Therapeutics, Inc. reported that President & CEO and director Malte Peters received new equity awards. On January 8, 2026, he was granted 350,000 restricted stock units (RSUs) of common stock at a grant price of $0.00, increasing his directly held common shares to 367,500. Each RSU represents one share of common stock and will vest over three years: 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service.
He was also granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036. This option vests over four years, with 25% vesting on January 8, 2027 and the remainder vesting in 36 substantially equal monthly installments thereafter, contingent on continued service, leaving him with 1,650,000 options beneficially owned.